(132 Total References)
You are here: Home / Scientific ...
You are here: Home / Scientific Advisory Board / Jeffrey Lieberman, M.D.
Jeffrey Lieberman, M.D.
Jeffrey A. Lieberman, MD, is a physician and scientist who has spent his career of over 25 years caring for patients and studying the nature and treatment of mental illness.
Jeffrey A. Lieberman, M.D., is the Lawrence C. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute.
He also holds the Lieber Chair for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as Psychiatrist in Chief at NewYork-Presbyterian Hospital - Columbia University Medical Center.
Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975.
postgraduate training in psychiatry at St. Vincent's Hospital
and Medical Center of New York Medical College
was on the faculties of the Albert Einstein College of Medicine
and Mount Sinai School of Medicine
Prior to moving to Columbia University, he was Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Center at the University of North Carolina at Chapel Hill School of Medicine.
Dr. Lieberman's research
has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations
and has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders.
In this context, his
work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.
In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH.
He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.
work has been reported in more than 450 articles in the scientific literature and he
has edited or co-edited 12 books, including the textbook Psychiatry, currently in its third edition; Textbook of Schizophrenia
, Comprehensive Care of Schizophrenia; Psychiatric Drugs; and Ethics in Psychiatric Research: A Resource Manual on Human Subjects Protection.
He also serves, or has served, as Associate Editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, Neuroimage, International Journal of Neuropsychopharmacology, and the Schizophrenia Bulletin.
Dr. Lieberman is a member of the National Academy of Sciences Institute of Medicine and a fellow of the American Association for the Advancement of Science (AAAS).
He is a recipient of the Lieber Prize for Schizophrenia Research from NARSAD, the Adolph Meyer Award from the American Psychiatric Association, the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatry, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Gralnick Award for Schizophrenia Research, the Ziskind-Somerfeld Award of the Society of Biological Psychiatry, the Ernest Strecker Award of the University of Pennsylvania, the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill, and the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research.
He is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General's Report on Mental Health, the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA), the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, and the National Advisory Mental Health Council of the National Institute of Mental Health.
He is currently Vice President of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) and chairs the Council on Research and Quality Care for the American Psychiatric Association (APA).
resides with his
wife and two sons in New York City.
Jeffrey Lieberman, M.D.
Dr. Jeffrey Lieberman, chair ...
Dr. Jeffrey Lieberman, chair of the Columbia University Department of Psychiatry*
Jeffrey Lieberman, MD, is the Lawrence C. Kolb Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons; Director, New York State Psychiatric Institute; and Psychiatrist-in-Chief, New York Presbyterian Hospital- Columbia University Medical Center.
work has advanced our knowledge of the natural history, pathophysiology and treatment of schizophrenia and related psychotic disorders.
This research has fundamentally contributed to our current standards of care, the development of novel therapeutic drugs and the transformative mental health care strategy for the early detection and prevention of schizophrenia.
has authored more than 500 papers and articles published in the scientific literature and written and/or edited ten books on mental illness and psychiatry.
is the recipient of many honors and awards, including the Lieber Prize
for Schizophrenia Research from the Brain and Behavior Research Association
, the Adolph Meyer and Research Awards from the American Psychiatric Association
, the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmaology
He is a member of numerous scientific organizations and in 2000 was elected to the National Academy of Sciences Institute of Medicine.
Dr. Lieberman is the immediate past President of the American Psychiatric Association.
resides with his
wife and two sons in New York City.
Dr. Jeffrey Lieberman, a professor of psychiatry and pharmacology at the University of North Carolina, said that the agency's action suggested that antidepressants had become too popular and physicians too casual about dispensing them.
Forbes.com: Lilly Ferociously Defends Its Top Seller
"I think they're sort of being forced into this by the personal-injury lawyers who now see this as a source of revenue," says Jeffrey Lieberman, a psychiatrist at the University of North Carolina, Chapel Hill, who is conducting a trial comparing major schizophrenia drugs for the National Institutes of Health.
Lieberman conducted pivotal trials on Abilify, a schizophrenia drug from Bristol-Myers Squibb (nyse: BMY) and Otsuka Pharmaceuticals that has made its lack of weight gain a major selling point.
does not see giving up on Zyprexa yet, even as a first choice.
Less than half of patients on the drug gain significant weight, he
says, and many physicians are comfortable prescribing it.
sees drugs with less potential for making patients fat, such as Abilify
(nyse: PFE) Geodon, as options for switching patients who have trouble.
Young patients also might benefit, he
says, as they are more likely to gain weight on Zyprexa and more likely to stop treatment because of it.
says that decision "flies in the face" of available evidence.
Abilify: A Breakthrough For Schizophrenia Patients
"The side-effect profile looks amazingly clean," says Jeffrey A. Lieberman, vice chair of psychiatry at the University of North Carolina in Chapel Hill Medical School."It's almost too-good-to-be-true clean."
Abilify, or aripiprazole, doesn't appear to cause weight gain like Eli Lilly's Zyprexa, nor does it stiffen muscles like Johnson & Johnson's Risperdal.It also doesn't cause the cardiac rhythm disturbances that have plagued another entrant, Pfizer's Geodon.
That's good news, especially given some studies showing that one-fifth of all patients go off their medicines because of side effects.
"Ultimately," says Lieberman
, "if it works like it's advertised and like the studies indicate, then it's a strong candidate for first-line treatment because you're putting people on it and never exposing them to side effects."
If you participated in the Abilify clinical trials or have comments on this new schizophrenia drug, how about sharing them on our bulletin board.
More on Abilify:
Abilify Pharmacology - Usage, Dosage, Side-Effects "Abilify" (Aripiprazole) Gets FDA Approval